Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine

G. N. Hortobagyi, H. Y. Yap, C. L. Wiseman, G. R. Blumenschein, A. U. Buzdar, S. S. Legha, J. U. Gutterman, E. M. Hersh, G. P. Bodey

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. In addition, nonspecific immunotherapy with either Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, and incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this five-drug combination.

Original languageEnglish (US)
Pages (from-to)157-159
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number1
StatePublished - Aug 18 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine'. Together they form a unique fingerprint.

Cite this